#China #Shanghai #CMO #Pulnovo Medical #Dr. Francis Duhay

Pulnovo Medical Enhances Leadership Team with New CMO

In a significant move to strengthen its leadership team, Pulnovo Medical, a global frontrunner in innovative therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), has appointed Dr. Francis Duhay as its Global Chief Medical Officer. Announced on August 25, 2025, this appointment marks a strategic enhancement geared toward advancing Pulnovo's vision in international markets.

Dr. Francis Duhay: A Proven Leader in Medical Innovation

Dr. Duhay, who holds board certifications in General and Cardiothoracic Surgery, comes to Pulnovo with over 25 years of experience in clinical medicine, medical device innovation, and executive leadership. He previously served as the Chief Medical Officer at Edwards Lifesciences, a position from which he contributed significantly to the development and clinical validation of Transcatheter Aortic Valve Replacement (TAVR). This revolutionary cardiovascular procedure, recognized globally for its profound impact, has generated over $4 billion in annual revenue and has been adopted in more than 80 countries.

His extensive career is characterized by leadership over 88 clinical studies across various medical specialties, along with close collaboration with key regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS). This wealth of experience makes him an invaluable addition to the Pulnovo team.

Focus on Pulmonary Artery Denervation and Global Expansion

With Dr. Duhay’s expertise, Pulnovo aims to advance its Pulmonary Artery Denervation (PADN) program, a critical technology that stands to redefine treatment standards for patients suffering from PH and HF. His proven ability to bring transformative cardiovascular technologies from concept to widespread acceptance positions Pulnovo optimally for future growth and innovation.

The company envisions leveraging Dr. Duhay’s insights to shape its strategic direction in clinical therapies and expand its user base across various international markets.

The Future of Pulmonary Hypertension Therapy

Pulnovo Medical’s commitment to battling PH and HF is evident in its dedication to developing mechanism-driven therapies that potentially improve patient outcomes across the globe. Dr. Duhay's appointment signals a pivotal moment in the company's trajectory as it strives to refine its product offerings and assert its position in the global healthcare landscape.

Each step forward in this endeavor is propelled by the need for more effective medical interventions in the areas of cardiovascular health, and with Dr. Duhay at the helm of medical leadership, Pulnovo is expected to innovate significantly in therapy options for patients.

In conclusion, the addition of Dr. Francis Duhay to the executive team at Pulnovo Medical not only enhances the organization’s credibility but also signals an era of transformative growth, making it an exciting time for stakeholders and patients alike as they await new advancements in pulmonary and cardiac care solutions.